生物活性 | |||
---|---|---|---|
描述 | BAF312, also called Siponimod, is a selective, potent and brain-penetrant S1P receptor modulator used to treat multiple sclerosis, with EC50 values of 0.4nM and 5nM for S1P1 and S1P3 in GTPγS binding assay, respectively. Oral administration of 1mg/kg BAF312 markedly reduced peripheral lymphocyte count, a pharmacodynamic biomarker in autoimmune diseases for S1P1 activation, by 88% in Lewis rats at 8h post treatment, with a shorter duration of action than FTY720[1]. BAF312 also showed effect on S1P5 with EC50 of 0.98nM. Treatment with BAF312 at concentration of 1μM for 1h promote internalization of S1P1 receptors in CHO cells expressed myc-tagged human S1P1 receptors. Daily oral administration of BAF312 at dose of 0.3 or 3mg/kg for 24 days dose-dependently suppressed ongoing disease symptoms in rat EAE. BAF312 concentration-dependently activated the GIRK channel via S1P1 in atrial myocytes with EC50 value of 15.8nM[2]. | ||
作用机制 | BAF312 is structurally based on FTY720.[1] |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.68mL 1.94mL 0.97mL |
19.36mL 3.87mL 1.94mL |
参考文献 |
---|